Zhejiang Jolly Pharmaceutical Co Ltd (300181) — Cash Flow Reinvestment Rate
Zhejiang Jolly Pharmaceutical Co Ltd (300181) has a Cash Flow Reinvestment Rate of 0.15x as of June 2025, reinvesting CN¥56.30 Million (capex CN¥19.94 Million plus investments CN¥-36.36 Million) from operating cash flow of CN¥367.02 Million. See Zhejiang Jolly Pharmaceutical Co Ltd (300181) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Zhejiang Jolly Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2007–2025)
Historical reinvestment intensity for Zhejiang Jolly Pharmaceutical Co Ltd across 19 annual periods. For the full cash flow conversion analysis, see Zhejiang Jolly Pharmaceutical Co Ltd (300181) cash flow conversion.
Annual Cash Flow Reinvestment Rate for Zhejiang Jolly Pharmaceutical Co Ltd (2007–2025)
Year-by-year capital reinvestment analysis for Zhejiang Jolly Pharmaceutical Co Ltd. See Zhejiang Jolly Pharmaceutical Co Ltd leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.00x | CN¥412.14 Million | CN¥411.80 Million | CN¥287.14 Million | ▼ -28.3% |
| 2024 | 1.40x | CN¥414.53 Million | CN¥297.05 Million | CN¥262.89 Million | ▲ +1.8% |
| 2023 | 1.37x | CN¥395.29 Million | CN¥288.46 Million | CN¥131.71 Million | ▲ +88.0% |
| 2022 | 0.73x | CN¥232.28 Million | CN¥318.59 Million | CN¥178.03 Million | ▼ -26.9% |
| 2021 | 1.00x | CN¥251.15 Million | CN¥251.80 Million | CN¥147.95 Million | ▲ +116.1% |
| 2020 | 0.46x | CN¥129.08 Million | CN¥279.69 Million | CN¥58.35 Million | ▼ -25.8% |
| 2019 | 0.62x | CN¥80.22 Million | CN¥128.94 Million | CN¥40.46 Million | ▼ -83.0% |
| 2018 | 3.66x | CN¥286.30 Million | CN¥78.28 Million | CN¥153.92 Million | ▼ -84.3% |
| 2017 | 23.26x | CN¥151.37 Million | CN¥6.51 Million | CN¥124.40 Million | ▲ +266.4% |
| 2016 | 6.35x | CN¥370.19 Million | CN¥58.30 Million | CN¥143.24 Million | ▲ +132.5% |
| 2015 | 2.73x | CN¥265.21 Million | CN¥97.13 Million | CN¥26.08 Million | ▼ -4.8% |
| 2014 | 2.87x | CN¥39.30 Million | CN¥13.70 Million | CN¥39.30 Million | ▲ +256.8% |
| 2013 | 0.80x | CN¥23.73 Million | CN¥29.50 Million | CN¥23.73 Million | ▼ -33.8% |
| 2012 | 1.21x | CN¥37.05 Million | CN¥30.51 Million | CN¥37.05 Million | ▼ -73.0% |
| 2011 | 4.49x | CN¥61.32 Million | CN¥13.65 Million | CN¥61.32 Million | ▲ +652.1% |
| 2010 | 0.60x | CN¥38.68 Million | CN¥64.78 Million | CN¥38.68 Million | ▲ +33.7% |
| 2009 | 0.45x | CN¥19.60 Million | CN¥43.89 Million | CN¥19.60 Million | ▲ +11.3% |
| 2008 | 0.40x | CN¥12.50 Million | CN¥31.16 Million | CN¥12.50 Million | ▼ -29.4% |
| 2007 | 0.57x | CN¥9.12 Million | CN¥16.05 Million | CN¥9.12 Million | — |